Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fentanyl, quantity: 5.1 mg - drug delivery system, transdermal - excipient ingredients: dimeticone 360; methylated trimethylated silica; heptane; polyethylene terephthalate; polyvinylidene flouride; titanium dioxide; potable water; trolamine; strong ammonia solution; industrial methylated spirit; styrene/acrylates copolymer; polyethylene; polytef; dimeticone 350; docusate sodium; propylene glycol; purified water; acrylates copolymer; methoxyisopropyl acetate; 2-ethylhexyl acrylate; ethyl acetate; polyisocyanate; 4,4'-diphenylmethane diisocyanate; silane; polypropylene; ethylene/propylene copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; tris(2,4-ditert-butyphenyl) phosphite; calcium stearate; aluminium magnesium hydroxide carbonate; perflouropropylene/vinylidene diflouride copolymer; 1,3,5-trimethyl-2,4,6-tris(3,5-ditert-butyl-4-hydroxybenzyl)benzene; aluminium calcium sodium silicate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; iron oxide red; pigment yellow 119; zinc stearate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 6.3 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - fentanyl, quantity: 16.5 mg - drug delivery system, transdermal - excipient ingredients: titanium dioxide; polypropylene; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - fentanyl, quantity: 12.375 mg - drug delivery system, transdermal - excipient ingredients: polypropylene; polyethylene terephthalate; titanium dioxide; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - fentanyl, quantity: 8.25 mg - drug delivery system, transdermal - excipient ingredients: titanium dioxide; polypropylene; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - fentanyl, quantity: 4.125 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; titanium dioxide; polypropylene; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - fentanyl, quantity: 2.063 mg - drug delivery system, transdermal - excipient ingredients: polypropylene; polyethylene terephthalate; titanium dioxide; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - fentanyl, quantity: 16.5 mg - drug delivery system, transdermal - excipient ingredients: titanium dioxide; polypropylene; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - fentanyl, quantity: 12.375 mg - drug delivery system, transdermal - excipient ingredients: titanium dioxide; polypropylene; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

grunenthal ltd - buprenorphine - transdermal patch - 35microgram/1hour